Search

Bioterrorist attacks occupy a special place amongst the innumerable potential types of terrorist attack, with the intentional release of pox viruses being especially feared in this connection. Apart from the variola virus, the agent responsible for smallpox in humans, the monkeypox virus and numerous other animal pox viruses pose potential risks for humans and animals. This risk scenario also includes recombinations between the various pox viruses, changes in hosts and genetically engineered manipulations of pox viruses. For over 200 years, the method of choice for combatting smallpox was via vaccination with a reproductive, original vaccinia virus. Worldwide eradication of smallpox at the end of the 1970s and the discontinuation of routine smallpox vaccination in 1980 can be credited to such vaccination. Unfortunately, these vaccinations were associated with a large number of postvaccinal impairments, sometimes resulting in death (e.g. postvaccinal encephalitis). The only way to restrict such postvaccinal complications was to carry out initial vaccination within the first 2 postnatal years. Initial vaccination at a later age led to such a sharp increase in the number of vaccines with complications that vaccination had to be discouraged. The dilemma of the smallpox vaccine stocks stems from the fact that a large portion of these stocks are produced with the same vaccinia strains as before. This is irresponsible, especially as the percentage of immune-suppressed persons in the population, for whom vaccination-related complications pose an especial threat, is increasing. One solution to the dilemma of the smallpox vaccine stocks is the MVA strain. It is harmless, protects humans and animals equally well against smallpox and can be applied parenterally.

The reptilian paramyxoviruses FDLV and GOV initiated the production and release of cytokines like IL-1alpha, IL-1beta, IL-2, TNF-alpha and IFN-alpha in human peripheral blood mononuclear cells (PBMC) at 37 degrees C. The target cells produced the cytokines without replication of virus.

The poxvirus preparation CONPIND initiated the production of the two major inflammatory mediators interleukin-1 alpha (IL-1 alpha) and tumour necrosis factor-alpha (TNF-alpha) in whole blood and in blood mononuclear cell cultures of man at 37 degrees C within 12-48 h. The release of the cytokines followed a dose-efficacy curve. High levels of IL1-alpha (up to 810 pg/ml) and TNF-alpha (up to 533 pg/ml) were determined by sandwich enzyme-linked immunosorbent assay.

The interferon (IFN)-inducing capacities of intact NDV virions, β-propiolactone-inactivated particles and several structural components were compared, using human PBML as the IFN producing cells. Intact and inactivated virions as well as the nucleocapsid fraction did not differ significantly in their IFN-inducing capacity. In contrast, genomic RNA as well as M protein fraction and envelopes induced IFN titres to a level of about 10% of those achieved with virions. NDV-induced IFN production could be blocked specifically by incubation with polychonal anti-NDV-monoclonal antibodies (mAbs) and with two of three anti-HN-mAbs, but not with anti-NDV-mAbs directed against the F, M or NP protein. In addition, IFN induction by fixed MDBK cells, expressing NDV surface proteins after infection with NDV Ulster, was inhibited by one of two anti-F-mAbs. The results suggest that the induction of IFN synthesis in human PBML is a complex process involving not only the HN protein but also the uncleaved F protein precursor, a component of the M protein fraction and — once having entered the cell — the genomic RNA.

Despite many attempts to find reliable in vitro criteria for the efficacy of Biological Response Modifiers--BRMs (immunomodulators, paramunity inducers) animal challenge models are still the only way to demonstrate the totality of interlocking defense mechanisms. Challenge models with mouse pathogenic viruses provide an excellent possibility to study protective effects of BRMs against acute or chronic forms of viral diseases. For comparative studies two completely different virus challenge models--Pseudorabies PR and Stomatitis Vesicularis VSV--were developed with adult and baby NMRI mice respectively. The potency of BRMs in preventing lethal disease reveals significant differences depending upon the sort of BRM, the route of application and the time of pretreatment. Defense mechanisms important for the control of Pseudorabies virus infection in adult NMRI mice were tested in vitro (ex vivo) and correlated well with the degree of protection in vivo. Comparison of BRM efficacy in selective viral challenge models combined with screening of a variety of antiviral defense functions in infected animals in vitro provide reliable methods in demonstrating the potency of BRMs against viral infections.

Mandatory vaccination against smallpox was abolished on the account of smallpox-eradication proclaimed by the WHO and the postvaccinal complications detected after smallpox vaccination. At the same time vaccine banks with the vaccinia virus strain "Elstree" were organized. Should mass vaccinations with this vaccinia virus strain be carried out in a case of emergency, severe postvaccinal diseases and complications can arise in overaged and immunosuppressed vaccinees after primovaccination. Therefore attenuated vaccinia virus strains should be used for vaccine banks, which cannot be activated, or increase in virulence in impaired vaccinees after primovaccination. For these individuals the vaccinia virus strain "MVA", among other attenuated vaccinia strains, is recommended. The MVA virus strain can be applied parenterally without complications. From the scientific and field-relevant point of view it was tried to combine the vaccinia virus strain "MVA" with tetanus toxoid and to develop a combination vaccine "tetanus-smallpox". In immunization experiments using mice, piglets and monkeys, safety and efficacy of the vaccine were investigated. Efficacy was demonstrated by means of postvaccinal antibody determination and by the mouse protection test. Tetanus antitoxin was measured by ELISA and indirect hemagglutination test, antibody levels to vaccinia virus were investigated employing the neutralization test and hemagglutination inhibition test. No significant differences in potency could be demonstrated between the combination vaccine and the corresponding monovalent vaccines in mice, piglets and monkeys. The combination vaccine consisted of 12 Lf tetanus toxoid and 10 TCID50 vaccinia virus "MVA" preserved with gelatine and glucosamine. The double intramuscular immunization of monkeys stimulated average tetanus antitoxin titers of 1:310 and average vaccinia virus titers of 1:195 2 weeks p. revacc. Similar results were obtained in mice and piglets. Side reactions were not observed in mice and piglets. Except for occasional local reactions of short duration at the injection site of the monkeys, similarly no adverse reactions were observed after intramuscular vaccination with the combination vaccine.